Whalesbook
Financial Highlights: Record Quarter and Year
Laurus Labs' latest earnings report reveals strong financial performance, pushing its stock to a record high. In the fiscal fourth quarter ending March 2026, the company reported revenue of ₹1,812 crore, up 5% year-over-year, and EBITDA of ₹523 crore, a 10% annual increase. These results were supported by solid EBITDA margins of 28.9%, driven by ongoing operating leverage and a favorable product mix.
For the full fiscal year 2025-2026, Laurus Labs achieved substantial growth, with revenue increasing 23% to ₹6,813 crore. EBITDA for the year surged 64% to ₹1,826 crore. Gross margins also improved significantly, climbing over 5 percentage points to 60.4%. The stock reacted positively, trading at ₹1,141.05, up 5.8%, surpassing its previous high of ₹1,144.50 set on April 20, 2026. Trading volumes were notably high, with 2.91 million shares exchanged.
CDMO Strength and Investment Returns
The Contract Development and Manufacturing Organization (CDMO) segment has become a key engine for Laurus Labs' growth. After a recent slowdown, this division is showing strong recovery, with revenue up 38% year-over-year. This rebound is thanks to ongoing business from existing clients and successful project launches. Over the last two years, the CDMO's quarterly revenue run rate has effectively doubled, growing from ₹220-250 crore to ₹450-500 crore. This has boosted its share of total revenue from 16% to 28%, contributing significantly to margin expansion. Laurus Labs' strategic capital investments of around ₹4,300 crore between FY22 and FY26, with nearly 79% allocated to API and CDMO facilities, are now proving beneficial. The company is also exploring new areas like Cell and Gene therapies, indicating a strategy to expand beyond its established anti-retroviral (ARV) business.
Valuation Insights and Peer Comparisons
Analysts are closely observing Laurus Labs' growth. Motilal Oswal Financial Services noted that the company's capacity expansions and significant CDMO/API capital expenditure (₹3,900 crore over FY22-26) are helping it convert pipeline opportunities faster than rivals.
However, the market's valuation of Laurus Labs is drawing attention. As of late April 2026, its Price-to-Earnings (P/E) ratio is between 64.0x and 74.11x. This valuation is considered high when compared to peers like Syngene International (P/E around 43.0x-59.64x) and Divi's Laboratories (P/E around 65.1x-69.67x). Some assessments suggest Laurus Labs is trading at a premium, with GuruFocus rating it 'Significantly Overvalued' based on its GF Value™ of ₹627.07 against a share price of ₹1,113.45.
The wider CDMO market is expanding rapidly, projected to reach USD 210.53 billion by 2031 at an 8.61% CAGR. This growth is driven by factors including supply chain resilience and demand for complex molecules, alongside geopolitical trends favoring regionalized supply chains.
Despite the positive industry outlook, analyst sentiment on Laurus Labs is split. Motilal Oswal has a 'BUY' rating with a target of ₹1,280. However, other reports suggest a mixed consensus of 'Neutral' or 'Hold', with some analysts recommending 'Sell.' Price targets range widely from ₹510 to ₹1,270. Laurus Labs' stock has performed strongly year-to-date, increasing by 77.42% over the past year.
Investor Concerns and Potential Risks
While Laurus Labs's recent results and stock performance are positive, several factors warrant caution. The company's high valuation, with P/E ratios well above its historical median, suggests its current stock price may already reflect substantial future growth expectations.
Key risks include sensitivity to global pharmaceutical demand cycles, potential impacts from currency fluctuations on export earnings, and growing competition in the lucrative CDMO sector. The success of new technology investments, such as Cell and Gene therapies, will depend on effective transition and scaling.
Furthermore, the divided analyst consensus, with a significant number advising 'Sell' or 'Hold,' indicates a lack of universal market confidence in sustained outperformance. The wide range of price targets also reflects uncertainty about the company's future earnings and the long-term viability of its growth strategies. Investors must also consider the execution risks tied to the company's considerable capital expenditure and its strategic diversification efforts.
Looking Ahead: Strategy and Challenges
Laurus Labs' management remains confident in its strategy, focusing on investments in new technologies and integrated capabilities to build future growth. The company expects continued strong demand for its CDMO and Affordable Medicines products.
Moving forward, Laurus Labs must successfully manage its valuation concerns, maintain a competitive edge in the dynamic CDMO market, and integrate its new technology initiatives. Investors will closely watch its ability to meet earnings targets, effectively manage capital expenditure, and navigate global economic uncertainties.